To evaluate the safety and tolerance of human CD19 targeted T Cells injection for the
treatment of relapsed and refractory CD19-positive diffuse large B-cell lymphoma and
follicular lymphoma. Patients will be given a conditioning chemotherapy regimen of
fludarabine and cyclophosphamide followed by a single infusion of CD19 CAR+ T cells.
Participants with relapsed/refractory CD19-positive Diffuse Large B-cell Lymphoma and
Follicular Lymphoma can participate if all eligibility criteria are met.Tests required to
determine eligibility include disease assessments, a physical exam, Electrocardiograph,
CT/MRI , and blood draws.Participants receive chemotherapy prior to the infusion of CD19 CAR+
T cells. After the infusion, participants will be followed for side effects and effect of
CD19 CAR+ T cells. Study procedures may be performed while hospitalized.
Diffuse Large B-Cell Lymphoma,
diffuse large cell lymphoma,
diffuse large b cell lymphoma
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.